Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Editas Medicine

5 Disclosed Funding Rounds $656,600,000

0 Participating Investments


Health Care, Genetics, Biotechnology, Medical

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

Cambridge, Massachusetts, United States, North America (US)

Organizations in Cambridge in Health Care,
Organizations in Cambridge in Genetics,
Organizations in Cambridge in Biotechnology,
Organizations in Cambridge in Medical,
Organizations in Massachusetts in Health Care,
Organizations in Massachusetts in Genetics,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Medical,
Organizations in United States in Health Care,
Organizations in United States in Genetics,
Organizations in United States in Biotechnology,
Organizations in United States in Medical,
Organizations in North America in Health Care,
Organizations in North America in Genetics,
Organizations in North America in Biotechnology,
Organizations in North America in Medical

Investors in Cambridge in Health Care,
Investors in Cambridge in Genetics,
Investors in Cambridge in Biotechnology,
Investors in Cambridge in Medical,
Investors in Massachusetts in Health Care,
Investors in Massachusetts in Genetics,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Medical,
Investors in United States in Health Care,
Investors in United States in Genetics,
Investors in United States in Biotechnology,
Investors in United States in Medical,
Investors in North America in Health Care,
Investors in North America in Genetics,
Investors in North America in Biotechnology,
Investors in North America in Medical

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 2013

Founders J. Keith Joung, Jennifer Doudna, Feng Zhang

Operating Status Active

Funding Stage IPO

Last Funding Type Post-IPO Equity

Company Type For Profit


Facebook Link

Twitter Link

LinkedIN Link

Wikipedia Link

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Date Round Raised Lead
January, 21, 2021 Post-IPO Equity $231,000,000 -------
June, 23, 2020 Post-IPO Equity $215,600,000 -------
August, 10, 2015 Series B $120,000,000 Boris Nikolic
May, 27, 2015 Undisclosed $47,000,000 Juno Therapeutics
November, 25, 2013 Series A $43,000,000 Flagship Pioneering, Polaris Partners, Third Rock Ventures

Editas Medicine Investors (17)

Investor Lead? Round Participating Raise Date Partners
Jennison Associates No Series B $120,000,000 August, 10, 2015 -------
Flagship Pioneering No Series B $120,000,000 August, 10, 2015 -------
Khosla Ventures No Series B $120,000,000 August, 10, 2015 -------
Omega Funds No Series B $120,000,000 August, 10, 2015 -------
Boris Nikolic Yes Series B $120,000,000 August, 10, 2015 -------
Third Rock Ventures No Series B $120,000,000 August, 10, 2015 -------
Polaris Partners No Series B $120,000,000 August, 10, 2015 -------
GV No Series B $120,000,000 August, 10, 2015 -------
EcoR1 Capital No Series B $120,000,000 August, 10, 2015 -------
Fidelity Management and Research Company No Series B $120,000,000 August, 10, 2015 -------
T. Rowe Price No Series B $120,000,000 August, 10, 2015 -------
Viking Global Investors No Series B $120,000,000 August, 10, 2015 -------
Juno Therapeutics Yes Undisclosed $47,000,000 May, 27, 2015 -------
Flagship Pioneering Yes Series A $43,000,000 November, 25, 2013 -------
Polaris Partners Yes Series A $43,000,000 November, 25, 2013 -------
Third Rock Ventures Yes Series A $43,000,000 November, 25, 2013 -------
Partners Innovation Fund No Series A $43,000,000 November, 25, 2013 -------